Bayer
BAYRY | OTC
$15.61
-$0.05 (-0.32%)
At close: Nov 16, 2026, 3:59 PM ET
$15.60
-$0.01 (-0.06%)
After-hours:
Nov 16, 2026, 4:00 PM ET
Bayer Company Profile
Company profile explainedCompany Profile
Bayer Aktiengesellschaft, commonly known as Bayer AG, functions as a prominent global life sciences company through its various subsidiaries. Its extensive operations are strategically segmented into Pharmaceuticals, Consumer Health, and Crop Science. The Pharmaceuticals division concentrates on developing and marketing prescription medications, with key areas including cardiology and women's healthcare. It also offers specialized therapeutic solutions for oncology, hematology, and ophthalmology, alongside diagnostic imaging equipment, contrast agents, and advanced cell and gene therapies. Bayer's Consumer Health segment provides a wide array of non-prescription (over-the-counter) medicines, medical devices, medicated skincare items, and nutritional supplements. These self-care products address diverse health needs such as dermatology, dietary support, pain relief, cardiovascular risk prevention, digestive issues, allergy management, and cold and cough symptoms. The Crop Science division supports the agricultural sector with chemical and biological crop protection products, genetically enhanced plant traits, seeds, digital farming tools, and solutions for pest and weed control. This segment also manages the breeding, propagation, production, and specialized treatment of seeds, complemented by dedicated customer service for farmers. Bayer is actively involved in numerous strategic collaborations to bolster its research and development pipeline. These partnerships include an agreement with MD Anderson Cancer Center for oncology drug development, a research and licensing deal with Dewpoint Therapeutics, Inc. focused on novel treatments for cardiovascular and gynecological diseases, and collaborations with Exscientia Ltd, Foundation Medicine Inc., Evotec AG, and Arvinas Inc. Additionally, the company maintains strategic research alliances with the University of Oxford for gynecological therapies and with Kyoto University to discover potential new drugs for pulmonary conditions. The company’s products reach a broad market through various distribution channels, including wholesale partners, independent and chain pharmacies, supermarkets, online and other retail outlets, hospitals, and direct sales to agricultural producers. Bayer Aktiengesellschaft was established in 1863 and is headquartered in Leverkusen, Germany.
Key Executives
| Name | Position |
|---|---|
| William N. Anderson | Chairman of the Management Board & Chief Executive Officer |
| Alex Buschermohle | Chief Information Officer, Head-Digital Transformation & IT-Crop Science Division |
| Judith Hartmann | Chief Financial Officer & Member of Management Board |
| Bill Dodero | General Counsel and Senior Vice President of Law Patents & Compliance |
| Heike Prinz | Chief Talent Officer, Labor Director & Member of Management Board |
| Jana Marlen Ackermann | Head of the Investor Relations |
| Julio Triana | Member of Management Board & President of Consumer Health Division |
| Michael Preuss | Head of Communications, Government Relations and Corporate Brand |
| Rodrigo Santos | Member of Management Board, Head of the Crop Science Division & President of Crop Science Division |
| Stefan Oelrich | President of the Pharmaceuticals Division & Member of the Board of Management |
Bayer
| Country | Germany |
| IPO Date | Nov 18, 1996 |
| Industry | Drug Manufacturers - General |
| Sector | Healthcare |
| Employees | 88,078 |
| CEO | Bill Anderson |
Contact Details
Kaiser-Wilhelm-Allee 1 Leverkusen,
NW 51368 Germany
Stock Details
| Ticker Symbol | BAYRY |
| Exchange | OTC |
| Fiscal Year | n/a |
| Reporting Currency | USD |
| CIK Code | n/a |
| CUSIP Number | 072730302 |
| ISIN Number | US0727303028 |
| SIC Code | n/a |
Recent News
- 6 days ago / zacks.comBayer Wins FDA Approval for Sunharbo for Secondary Stroke Risk Reduction
- 7 days ago / businesswire.comBayer's SUNHARBO® (asundexian), 50 mg tablets, the First and Only Factor XIa Inhibitor, Approved by the U.S.
- 8 days ago / zacks.com3 Large-Cap Stocks to Watch as Drug & Biotech Sector Rebounds in 2026
- 12 days ago / zacks.comBAYRY vs. JNJ: Which Stock Is the Better Value Option?
- 12 days ago / zacks.comAre Medical Stocks Lagging Bayer (BAYRY) This Year?
- 13 days ago / businesswire.comBayer and America's Grow-a-Row Continue Partnership to Fight Food Insecurity
- 13 days ago / reuters.comBayer seeks bigger role in fast-growing Latin American biologicals market
- 13 days ago / zacks.comBAYRY Q3 Earnings and Revenues Miss Estimates, Pharma Performs Well
- 13 days ago / businesswire.comBayer to Present New Cardiovascular, Kidney and Stroke Data at the 2026 American Heart Association (AHA) Scientific Sessions
- 13 days ago / seekingalpha.comBayer AG: Solid Q3 Earnings, But Still A 'Prove-It' Story
Add to Watchlist
Select watchlists to add or remove BAYRY